Genzyme Corp. and Isis Pharmaceuticals, Inc. have formed a strategic alliance in which Genzyme will develop and commercialize mipomersen, Isis’ lipid-lowering treatment for high-risk cardiovascular patients that uses novel antisense technology. As part of the alliance, Genzyme will have preferred access to future Isis drugs for CNS and certain rare diseases. Genzyme will buy a $150 million equity investment in Isis and pay a $175 million up front for a mipomersen license fee. Isis may...